Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Study Overview
=================
Brief Summary
-----------------
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction > 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 820 in Part B.

Official Title
-----------------
A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Conditions
-----------------
Heart Failure With Preserved Ejection Fraction

Intervention / Treatment
-----------------
* Drug: AZD4831
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Part A ≥ 40 to ≤ 85 years of age, at the time of signing the informed consent. Documented stable symptomatic HF (New York Heart Association Class II-IV) for at least 1 month at Screening (Visit 1) (transient HF in the setting of an MI does not qualify), with a medical history of typical symptoms of HF and receiving optimal therapy for HF as determined by the health-care physician. LVEF > 40% at Screening (Visit 1). All participants will undergo a local echocardiogram at the Screening (Visit 1) with central reading to confirm the LVEF > 40% eligibility criteria before randomisation. 6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 3). Difference in 6MWD between Screening and Randomisation must be < 50 meters. KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 3) NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤30 kg/m2. NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI > 30 kg/m2. The ECG performed at Screening should be used for heart rhythm evaluation. 7.At least one of the following: Structural heart disease, ie, LA enlargement and/or left ventricular hypertrophy at the echocardiogram performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI > 34 mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or LVMI > 95 g/m2 in women and > 115 g/m2 in men. Spectral tissue Doppler echocardiography - E/e' ratio (average of septal and lateral) ≥ 13 at rest at the echocardiogram performed at Screening (Visit 1). Indirectly estimated elevation of PASP by TRmax velocity > 2.8 m/s (280 cm/s) (PASP > 35 mmHg) at the echocardiogram performed at Screening (Visit 1) OR directly measured pulmonary capillary wedge pressure > 15 mmHg at rest within the past 12 months or > 25 mmHg at exercise documented by right heart catheterisation within 12 months prior to Screening (Visit 1). HF decompensation within 6 months before Randomisation (Visit 3), defined as hospitalisation for HF or IV diuretic treatment for HF during an urgent, unscheduled visit without hospitalisation. 8.Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2 9.Male or female of non-childbearing potential. Part B Participant must be ≥ 40 to ≤ 85 years of age, at the time of signing the informed consent. Documented diagnosis of symptomatic HF (NYHA class II-IV) at Screening (Visit 1), and a medical history of typical symptoms/signs of heart failure ≥ 6 weeks before Screening (Visit 1), and receiving optimal therapy for HF as determined by the health-care physician, with at least intermittent need for diuretic treatment. LVEF >40% and evidence of structural heart disease (ie, left ventricular hypertrophy or left atrial enlargement [defined by at least one of the following:LA enlargement and/or left ventricular hypertrophy at the echocardiogram performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI > 34 mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or LVMI > 95 g/m2 in women and > 115 g/m2 in men.]) documented by the most recent echocardiogram, or cardiac magnetic resonance imaging within the last 12 months prior to Screening (Visit 1). If no echocardiogram is available, it can be performed at Screening (Visit 1). 6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 2). Difference in 6MWD between Screening and Randomisation must be < 50 meters KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 2). NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤ 30 kg/m2. NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI > 30 kg/m2. The ECG performed at Screening should be used for heart rhythm evaluation Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2 Male or female of non-childbearing potential. Exclusion Criteria: Part A 1 eGFR < 30 mL/min/1.73m2 (Chronic Kidney Disease-Epidemiology Collaboration formula) at Screening (Visit 1). 2. Systolic blood pressure < 90 mmHg or ≥ 160 mmHg if not on treatment with ≥ 3 blood pressure lowering medications or ≥ 180 mmHg irrespective of treatments at Randomisation 3. Heart rate > 110 bpm or < 50 bpm at Randomisation 4. Life expectancy < 3 years due to other reasons than cardiovascular disease. 5. History or ongoing allergy/hypersensitivity reactions to drugs (including but not limited to rash, angioedema, acute urticaria). 6. Presence of any disease or condition rather than HF constituting the main reason for limiting the ability to exercise/reduced exercise capacity. 7. Current decompensated HF and/or NT-proBNP > 5000 pg/mL at Screening (Visit 1) 8. Documented history of ejection fraction ≤ 40%.i.e. HF with recovered ejection fraction. Transient ejection fraction decrease e.g. in the setting of an MI does not apply 9. Any planned cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc). 10. Any cardiac event (eg, myocardial infarction, unstable angina), coronary revascularisation (percutaneous coronary intervention or coronary artery bypass grafting), ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronisation therapy device within 12 weeks prior to Screening (Visit 1) or between Screening and Randomisation. Patients who underwent a successful atrial fibrillation/flutter cardioversion, can be enrolled in the study after 4 weeks. 14. Hb < 110 g/L (male) and < 100 g/L (female) or iron-deficiency with/without anaemia requiring ongoing or planned IV iron treatment. 15. Participants with hyperthyroidism, uncontrolled hypothyroidism (including but not limited to TSH ≥10 mIU/mL), or any clinically significant thyroid disease as judged by the investigator. 18. ALT or AST ≥ 2 × ULN at Screening (Visit 1). 19. Pulmonary arterial hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening (Visit 1). 20. Any active infection requiring oral, intravenous or intramuscular treatment at Screening (Visit 1) and/or at Randomisation. 23 Any signs or confirmation of COVID-19 infection: Suspected (as judged by PI) or confirmed COVID-19 within the last 2 weeks prior to Screening (Visit 1) or at Randomisation. Hospitalisation for COVID-19 within the last 12 weeks prior to Screening (Visit 1). 24. Any concomitant medications known to be a potent CYP3A4 inducers or inhibitors, eg, itraconazole, rifampicin, clarithromycin, or propylthiouracil 29. Previous enrolment and randomisation in the present study. (Participants who where screened and screen failed and not randomised in Part A can be screened for possible entry to Part B). All exclusion criteria in Part A are applicable to Part B with the following exceptions: Exclusion criteria 4; 19 Exclusion Criteria specific for Part B only [criteria numeration for Part B] 4. Life expectancy < 2 years due to other reasons than cardiovascular disease. 11. HF due to any of the following: known infiltrative cardiomyopathy (eg, amyloid, sarcoid, lymphoma, endomyocardial fibrosis), active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), or uncorrected primary valvular disease. 18. Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening [Visit 1]).

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Part A 2.5 mg<br>AZD4831 2.5 mg | Drug: AZD4831<br>* AZD4831<br>|
| Experimental: Part A 5 mg<br>AZD4831 5 mg | Drug: AZD4831<br>* AZD4831<br>|
| Placebo Comparator: Part A Placebo<br>Placebo | Other: Placebo<br>* Placebo<br>|
| Experimental: Part B Dose based on Part A<br>AZD4831 Dose based on Part A | Drug: AZD4831<br>* AZD4831<br>|
| Placebo Comparator: Part B Placebo<br>Placebo | Other: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kansas City Cardiomyopathy Questionnaire -Total Symptom Score | Kansas City Cardiomyopathy Questionnaire -Total Symptom Score change from baseline at 16 weeks compared with placebo Part A. The score ranges from 0 to 100, where a higher score represents a better patient outcome | Baseline - 16 weeks | 
| Kansas City Cardiomyopathy Questionnaire -Total Symptom Score | Kansas City Cardiomyopathy Questionnaire-Total Symptom Score change from baseline at 24 weeks compared with placebo Part B. The score ranges from 0 to 100, where a higher score represents a better patient outcome. | Baseline - 24 weeks | 
| Six Minute Walk Distance | Six Minute Walk Distance change from baseline at 16 weeks compared with placebo Part A | Baseline - 16 weeks | 
| Six Minute Walk Distance | Six Minute Walk Distance change from baseline at 24 weeks compared with placebo Part B | Baseline - 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kansas City Cardiomyopathy Questionnaire-Total Symptom Score | Kansas City Cardiomyopathy Questionnaire -Total Symptom Score change from baseline at 24 and 48 weeks compared with placebo Part A. The score ranges from 0 to 100, where a higher score represents a better patient outcome. | Baseline - 24 and 48 weeks | 
| Six Minute Walk Distance | Six Minute Walk Distance change from baseline at 24 and 48 weeks compared with placebo Part A | Baseline - 24 and 48 weeks | 
| N-terminal pro-brain natriuretic peptide (NT-proBNP) | NT-proBNP change from baseline at 16, 24, and 48 weeks compared with placebo Part A | Baseline - 16, 24 and 48 weeks | 
| Left ventricular global longitudinal strain (LV-GLS) | LV-GLS change from baseline at 16 and 24 weeks compared with placebo Part A | Baseline - 16 and 24 weeks | 
| Left atrial volume index (LAVI) | LAVI change from baseline at 16 and 24 weeks compared with placebo Part A | Baseline - 16 and 24 weeks | 
| Left ventricular mass index (LVMI) | LVMI change from baseline at 16 and 24 weeks compared with placebo Part A | Baseline - 16 and 24 weeks | 
| Pharmacokinetics (AZD4831 plasma exposure) | Plasma concentrations of AZD4831 summarised by timepoint and dose level Part A | Day 1, Day 29, Day 85, Day 113, Day 169, Day 336, Day 365 | 
| High sensitivity CRP (hsCRP) | hsCRP change from baseline at 16, 24, and 48 weeks compared with placebo Part A | Baseline - 16, 24 and 48 weeks | 
| Interleukin 6 (IL-6) | IL-6 change from baseline at 16, 24, and 48 weeks compared with placebo Part A | Baseline - 16, 24 and 48 weeks | 
| High sensitivity CRP (hsCRP) | hsCRP primary assessment at 24 weeks Part B | Baseline - 24 weeks | 
| N-terminal pro-brain natriuretic peptide (NT-proBNP) | NT-proBNP primary assessment at 24 weeks Part B | Baseline - 24 weeks | 
| Interleukin 6 (IL-6) | IL-6 primary assessment at 24 weeks Part B | Baseline - 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, Heart failure with preserved ejection fraction, HFpEF